Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 26;25(4):344–353. doi: 10.3350/cmh.2019.0016

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Ultraselective conventional transarterial chemoembolization (cTACE) for hypovascular hepatocellular carcinoma. (A) Arterial phase computed tomography (CT) showed a hypovascular tumor in segment 4 (arrow) near the previously embolized tumor (arrowhead). (B) The tumor showed hyperintensity on diffusion-weighted magnetic resonance imaging (MRI) and hypointensity with a hyperintense rim on hepatobiliary-phase of gadoxetate disodium-enhanced MRI. (C) Common hepatic arteriogram showed no tumor staining. (D) TACE guidance software identified two tumor-feeders. (E, F) Each branch was selectively embolized using a 1.5-F tip microcatheter. The arrows indicate the tumor. (G) Unenhanced CT performed 1 week after ultraselective cTACE showed iodized oil accumulation in the entire tumor. (H) Arterial phase CT performed 1 year and 2 months after ultraselective cTACE showed complete tumor necrosis. DWI, diffusion-weighted image; HBP, hepatobiliary-phase.